{"id":68260,"date":"2021-01-22T12:18:36","date_gmt":"2021-01-22T11:18:36","guid":{"rendered":"https:\/\/cms.munich-startup.net\/?p=68260"},"modified":"2021-01-22T12:04:30","modified_gmt":"2021-01-22T11:04:30","slug":"gna-biosolutions-receives-special-approval-for-rapid-corona-test","status":"publish","type":"post","link":"https:\/\/cms.munich-startup.net\/en\/68260\/gna-biosolutions-receives-special-approval-for-rapid-corona-test\/","title":{"rendered":"GNA Biosolutions receives special approval for rapid corona test"},"content":{"rendered":"<div class=\"entry-content\">\n<p>The Munich startup, <a href=\"\/en\/day\/gna-biosolutions\/\">a spin-off from the Ludwig Maximilian University of Munich<\/a>has developed a new rapid coronavirus test. It is based on the PCR method, which detects the pathogen&#039;s genetic material. This makes the method significantly more reliable than the currently widely used rapid antigen tests. According to GNA Biosolutions, the rapid test achieves a sensitivity of 96.7 percent and a specificity of 100 percent, which is on par with standard PCR tests. <a href=\"https:\/\/gna-bio.com\/products\/\" target=\"_blank\" rel=\"noreferrer noopener\">\u201cGNA Octea\u201d<\/a> It only takes about 40 minutes from the throat swab to the test result, with 20 minutes for the throat swabs and preparation time and another 20 minutes for the actual test in the device.<\/p>\n\n\n\n<p>The development also includes portable testing devices that can evaluate up to eight samples simultaneously. This allows for a large number of rapid tests to be performed within a shorter period of time. As a mobile laboratory, the entire device requires only the space of a table and can be used anywhere without the need to transport the samples to a laboratory, as is the case with conventional PCR tests. This means that a test should cost less than 20 euros. The development of the test was commissioned by Bavarian Minister of Economic Affairs Hubert Aiwanger (Free Voters) in April and received eight million euros in funding.<\/p>\n\n\n\n<p><strong>Federico B\u00fcrsgens<\/strong>, CEO of GNA Biosolutions, explains:<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p>&quot;We are proud to have developed a testing system within just a few months that meets the highest standards. Our process is effective even with small amounts of virus. This allows us to combine reliability with speed at a comparatively low price. By awarding us the contract in April, the Bavarian Minister of Economic Affairs gave us the opportunity to bring our process to market readiness in a timely manner.&quot;<\/p><\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\">Back to normality thanks to GNA Biosolutions?<\/h2>\n\n\n\n<p><strong>Hubert Aiwanger<\/strong> adds:<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p>&quot;The new rapid test will help us contain the pandemic and specifically minimize infection risks. Especially from an economic perspective, it is an urgent concern that we provide sufficient rapid and reliable testing capacities to enable a return to more normality. Alongside our FFP2 masks made in Bavaria with German DEKRA certification, this rapid test from the Bavarian biotech industry is another major success in our work over the past few months to combat the coronavirus.&quot;<\/p><\/blockquote>\n\n\n\n<p>The Bavarian state government plans to test the usability of the testing procedure in several practical trials starting in mid-January. These will take place in Bavarian hospitals and other facilities such as slaughterhouses. For this purpose, the state government has ordered six of the new devices and 60,000 test kits. In addition, Bavaria has secured a purchase right for 1,000 devices and one million individual tests.<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>The Munich-based biotechnology company GNA Biosolutions has developed Bavaria&#039;s first PCR-based rapid coronavirus test. Thanks to special approval from the Federal Institute for Drugs and Medical Devices (BfArM), the test procedure, called &quot;GNA Octea,&quot; is now available.<\/p>","protected":false},"author":33,"featured_media":68262,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[5638,1],"tags":[3882,3276,731],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.1.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>GNA Biosolutions erh\u00e4lt Sonderzulassung f\u00fcr Corona-Schnelltest - Munich Startup<\/title>\n<meta name=\"description\" content=\"Das M\u00fcnchner Biotechnologie-Unternehmen GNA Biosolutions hat den ersten bayerischen Corona-Schnelltest auf PCR-Basis entwickelt.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cms.munich-startup.net\/en\/68260\/gna-biosolutions-receives-special-approval-for-rapid-corona-test\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GNA Biosolutions erh\u00e4lt Sonderzulassung f\u00fcr Corona-Schnelltest - Munich Startup\" \/>\n<meta property=\"og:description\" content=\"Das M\u00fcnchner Biotechnologie-Unternehmen GNA Biosolutions hat den ersten bayerischen Corona-Schnelltest auf PCR-Basis entwickelt.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cms.munich-startup.net\/en\/68260\/gna-biosolutions-receives-special-approval-for-rapid-corona-test\/\" \/>\n<meta property=\"og:site_name\" content=\"Munich Startup\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/munichstartup\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-22T11:18:36+00:00\" \/>\n<meta name=\"author\" content=\"Maximilian Feigl\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@munich_startup\" \/>\n<meta name=\"twitter:site\" content=\"@munich_startup\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Maximilian Feigl\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cms.munich-startup.net\/68260\/gna-biosolutions-erhaelt-sonderzulassung-fuer-corona-schnelltest\/\",\"url\":\"https:\/\/cms.munich-startup.net\/68260\/gna-biosolutions-erhaelt-sonderzulassung-fuer-corona-schnelltest\/\",\"name\":\"GNA Biosolutions erh\u00e4lt Sonderzulassung f\u00fcr Corona-Schnelltest - Munich Startup\",\"isPartOf\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cms.munich-startup.net\/68260\/gna-biosolutions-erhaelt-sonderzulassung-fuer-corona-schnelltest\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cms.munich-startup.net\/68260\/gna-biosolutions-erhaelt-sonderzulassung-fuer-corona-schnelltest\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2021\/01\/100318_o.jpg\",\"datePublished\":\"2021-01-22T11:18:36+00:00\",\"author\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/40ec2127e0b2a722f0cb734a53f43509\"},\"description\":\"Das M\u00fcnchner Biotechnologie-Unternehmen GNA Biosolutions hat den ersten bayerischen Corona-Schnelltest auf PCR-Basis entwickelt.\",\"breadcrumb\":{\"@id\":\"https:\/\/cms.munich-startup.net\/68260\/gna-biosolutions-erhaelt-sonderzulassung-fuer-corona-schnelltest\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cms.munich-startup.net\/68260\/gna-biosolutions-erhaelt-sonderzulassung-fuer-corona-schnelltest\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/68260\/gna-biosolutions-erhaelt-sonderzulassung-fuer-corona-schnelltest\/#primaryimage\",\"url\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2021\/01\/100318_o.jpg\",\"contentUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2021\/01\/100318_o.jpg\",\"width\":2400,\"height\":1413,\"caption\":\"Bayerns Wirtschaftsminister Hubert Aiwanger (links) pr\u00e4sentiert den ersten bayerischen PCR-Schnelltest gemeinsam mit GNA-CEO Dr. Federico B\u00fcrsgens, GNA-Laborantin Nicole Pill und Gesundheitsstaatssekret\u00e4r Klaus Holetschek (von links).\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cms.munich-startup.net\/68260\/gna-biosolutions-erhaelt-sonderzulassung-fuer-corona-schnelltest\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cms.munich-startup.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GNA Biosolutions erh\u00e4lt Sonderzulassung f\u00fcr Corona-Schnelltest\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cms.munich-startup.net\/#website\",\"url\":\"https:\/\/cms.munich-startup.net\/\",\"name\":\"Munich Startup\",\"description\":\"Das offizielle Startup-Portal f\u00fcr M\u00fcnchen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cms.munich-startup.net\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/40ec2127e0b2a722f0cb734a53f43509\",\"name\":\"Maximilian Feigl\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/194fab98a3d18da0d43ab2b73b348908?s=96&d=blank&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/194fab98a3d18da0d43ab2b73b348908?s=96&d=blank&r=g\",\"caption\":\"Maximilian Feigl\"},\"description\":\"Maximilian Feigl berichtet seit 2020 \u00fcber das M\u00fcnchner Startup \u00d6kosystem. Dabei haben es dem studierten Politikwissenschaftler vor allem Deeptech-Themen angetan.\",\"url\":\"https:\/\/cms.munich-startup.net\/en\/author\/feigl\/\"}]}<\/script>\n<meta property=\"og:image\" content=\"https:\/\/cms.munich-startup.net\/en\/wp-content\/uploads\/2021\/01\/100318_o.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2400\" \/>\n\t<meta property=\"og:image:height\" content=\"1413\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GNA Biosolutions receives special approval for rapid corona test - Munich Startup","description":"The Munich-based biotechnology company GNA Biosolutions has developed Bavaria&#039;s first PCR-based rapid coronavirus test.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cms.munich-startup.net\/en\/68260\/gna-biosolutions-receives-special-approval-for-rapid-corona-test\/","og_locale":"en_US","og_type":"article","og_title":"GNA Biosolutions erh\u00e4lt Sonderzulassung f\u00fcr Corona-Schnelltest - Munich Startup","og_description":"Das M\u00fcnchner Biotechnologie-Unternehmen GNA Biosolutions hat den ersten bayerischen Corona-Schnelltest auf PCR-Basis entwickelt.","og_url":"https:\/\/cms.munich-startup.net\/en\/68260\/gna-biosolutions-receives-special-approval-for-rapid-corona-test\/","og_site_name":"Munich Startup","article_publisher":"https:\/\/www.facebook.com\/munichstartup\/","article_published_time":"2021-01-22T11:18:36+00:00","author":"Maximilian Feigl","twitter_card":"summary_large_image","twitter_creator":"@munich_startup","twitter_site":"@munich_startup","twitter_misc":{"Written by":"Maximilian Feigl","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cms.munich-startup.net\/68260\/gna-biosolutions-erhaelt-sonderzulassung-fuer-corona-schnelltest\/","url":"https:\/\/cms.munich-startup.net\/68260\/gna-biosolutions-erhaelt-sonderzulassung-fuer-corona-schnelltest\/","name":"GNA Biosolutions receives special approval for rapid corona test - Munich Startup","isPartOf":{"@id":"https:\/\/cms.munich-startup.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cms.munich-startup.net\/68260\/gna-biosolutions-erhaelt-sonderzulassung-fuer-corona-schnelltest\/#primaryimage"},"image":{"@id":"https:\/\/cms.munich-startup.net\/68260\/gna-biosolutions-erhaelt-sonderzulassung-fuer-corona-schnelltest\/#primaryimage"},"thumbnailUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2021\/01\/100318_o.jpg","datePublished":"2021-01-22T11:18:36+00:00","author":{"@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/40ec2127e0b2a722f0cb734a53f43509"},"description":"The Munich-based biotechnology company GNA Biosolutions has developed Bavaria&#039;s first PCR-based rapid coronavirus test.","breadcrumb":{"@id":"https:\/\/cms.munich-startup.net\/68260\/gna-biosolutions-erhaelt-sonderzulassung-fuer-corona-schnelltest\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cms.munich-startup.net\/68260\/gna-biosolutions-erhaelt-sonderzulassung-fuer-corona-schnelltest\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/68260\/gna-biosolutions-erhaelt-sonderzulassung-fuer-corona-schnelltest\/#primaryimage","url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2021\/01\/100318_o.jpg","contentUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2021\/01\/100318_o.jpg","width":2400,"height":1413,"caption":"Bayerns Wirtschaftsminister Hubert Aiwanger (links) pr\u00e4sentiert den ersten bayerischen PCR-Schnelltest gemeinsam mit GNA-CEO Dr. Federico B\u00fcrsgens, GNA-Laborantin Nicole Pill und Gesundheitsstaatssekret\u00e4r Klaus Holetschek (von links)."},{"@type":"BreadcrumbList","@id":"https:\/\/cms.munich-startup.net\/68260\/gna-biosolutions-erhaelt-sonderzulassung-fuer-corona-schnelltest\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cms.munich-startup.net\/"},{"@type":"ListItem","position":2,"name":"GNA Biosolutions erh\u00e4lt Sonderzulassung f\u00fcr Corona-Schnelltest"}]},{"@type":"WebSite","@id":"https:\/\/cms.munich-startup.net\/#website","url":"https:\/\/cms.munich-startup.net\/","name":"Munich Startup","description":"The official startup portal for Munich","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cms.munich-startup.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/40ec2127e0b2a722f0cb734a53f43509","name":"Maximilian Feigl","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/194fab98a3d18da0d43ab2b73b348908?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/194fab98a3d18da0d43ab2b73b348908?s=96&d=blank&r=g","caption":"Maximilian Feigl"},"description":"Maximilian Feigl has been reporting on the Munich startup ecosystem since 2020. The political scientist is particularly interested in deeptech topics.","url":"https:\/\/cms.munich-startup.net\/en\/author\/feigl\/"}]},"og_image":[{"width":2400,"height":1413,"url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2021\/01\/100318_o.jpg","type":"image\/jpeg"}]},"_showyear":"","_inactive":"","_show_financing":"","_hide_on_map":"","_edit_lock":"1611314373:24","_edit_last":"24","_yoast_wpseo_focuskw":"GNA Biosolutions","_yoast_wpseo_metadesc":"Das M\u00fcnchner Biotechnologie-Unternehmen GNA Biosolutions hat den ersten bayerischen Corona-Schnelltest auf PCR-Basis entwickelt.","_yoast_wpseo_linkdex":"77","_thumbnail_id":"68262","wbounce_status":"default","_yoast_wpseo_primary_category":"5638","_yoast_wpseo_focuskw_text_input":"","_yoast_wpseo_content_score":"90","ms_image_format":"contentwidth","_ms_image_format":"field_5cb8587572c8b","ms_dachzeile":"","_ms_dachzeile":"field_5cd9b7f365df5","ms_bump_post_date":"","_ms_bump_post_date":"field_5d1341edcf42a","guest_author_name":"","_guest_author_name":"field_5cee78a6016f9","guest_author_image":"","_guest_author_image":"field_5cee7914016fb","guest_author_description":"","_guest_author_description":"field_5cee78dd016fa","ms_post_image_caption":"","_ms_post_image_caption":"field_5f735b0735284","ms_post_image_credit":"","_ms_post_image_credit":"field_5f735b1435285","suppress_startupbox":"","_suppress_startupbox":"","_yoast_wpseo_estimated-reading-time-minutes":"","_wp_old_date":"","_yoast_wpseo_title":"","_yoast_wpseo_wordproof_timestamp":"","footnotes":"","easy_language_simplification_original_id":"","easy_language_source_language":"","easy_language_simplification_language":"","easy_language_api":"","easy_language_prevent_automatic_mode":"","_wp_old_slug":"","_wp_trash_meta_status":"","_wp_trash_meta_time":"","easy_language_simplification_state_changed_from":"","easy_language_de_EL_changed":"","ms_competition_deadline":"","_ms_competition_deadline":"","_wpbitly":"","enclosure":"","_yoast_wpseo_meta-robots-noindex":"","_yoast_wpseo_meta-robots-nofollow":"","wbounce_template":"","wbounce_title":"","wbounce_text":"","wbounce_cta":"","wbounce_url":"","wbounce_override":"","_yoast_wpseo_opengraph-title":"","_yoast_wpseo_opengraph-description":"","_oembed_7131efca3705e16bd9da2c41df237660":"","_oembed_time_7131efca3705e16bd9da2c41df237660":"","_pprredirect_type":"","_pprredirect_url":"","_yoast_wpseo_opengraph-image":"","_yoast_wpseo_opengraph-image-id":"","_newsletterglue":"","easy_language_text_language":"","_wp_desired_post_slug":"","_relevanssi_noindex_reason":"","_links":{"self":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/68260"}],"collection":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/users\/33"}],"replies":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/comments?post=68260"}],"version-history":[{"count":3,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/68260\/revisions"}],"predecessor-version":[{"id":68279,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/68260\/revisions\/68279"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media\/68262"}],"wp:attachment":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media?parent=68260"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/categories?post=68260"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/tags?post=68260"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}